Bridgebio Pharma, Inc. (BBIO) Stock Price & Analysis

Bridgebio Pharma, Inc. (BBIO) rose 1.31% to USD 84.02 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.

BBIO last closed at USD 82.93; the session ranged USD 82.74–85.29 on volume of 2,030,538 shares. Market capitalization is $16.46B, with a 52-week range of USD 42.09–93.42 (NMS). Source: Nexqual, July 25, 2026 at 03:08 UTC.

Key Statistics (as of July 25, 2026 at 03:08 UTC)

Technical Analysis (BBIO)

Nexqual's technical model rates BBIO "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:08 UTC.

Analyst Ratings (BBIO)

Wall Street analysts rate BBIO "Strong Buy" based on 21 analysts, with a mean price target of USD 105.26 (range USD 80–157), per Nexqual as of July 25, 2026 at 03:08 UTC.

Earnings (BBIO)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 03:08 UTC.

Financials & Fundamentals (BBIO)

Source: Nexqual, July 25, 2026 at 03:08 UTC.

Financial Health Score (BBIO)

Nexqual rates Bridgebio Pharma, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:08 UTC.

Ownership (BBIO)

Source: Nexqual, July 25, 2026 at 03:08 UTC.

Leadership (BBIO)

Bridgebio Pharma, Inc. is led by Neil Kumar (age 46), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 03:08 UTC.

Major Backers & Investors (BBIO)

Notable institutional backers of Bridgebio Pharma, Inc. include Kohlberg Kravis Roberts & Co. L.P., Janus Henderson Group PLC, Viking Global, according to Nexqual as of July 25, 2026 at 03:08 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 03:08 UTC.

From Bridgebio Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• This efficiency allows us to work on a broad range of scientifically compelling therapies, including programs for underserved conditions which more traditional biopharmaceutical models might leave on the shelf but we believe can be developed on a Net Present Value ("NPV")-positive basis in our portfolio.
• This portfolio-based approach allows us to advance multiple programs in parallel and, over time, support a self-reinforcing "flywheel" of portfolio development.
• The following graphic illustrates our approach to program selection: Exhibit 1 1 As shown in Exhibit 1 above, we apply a quantitative approach to evaluating our programs and our Company as a whole, which typically includes the following factors: • Scientifically grounded program selection: Each program is selected based on strong biological validation, including a clear understanding of disease mechanism and a therapeutic approach designed to address a well-defined genetic condition.
• This model is intended to allow multiple programs to advance concurrently while enabling capital and other resources to be allocated flexibly as data evolves, consistent with our approach to managing development risk over time.

Partnerships

• We have licensed commercial rights in Europe to Bayer who are commercializing Beyonttra in all EU member states, the United Kingdom, Switzerland and Turkey under our Exclusive License Agreement with Bayer signed in March 2024.
• Outside the United States, acoramidis is marketed as Beyonttra™ and is commercialized through strategic collaboration partners, including Bayer in Europe and Alexion in Japan, as well as directly by BridgeBio in certain international markets.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.